containing Chlamydia LPS. The differences among the individual measurements were of borderline statistical significance, especially after adjustment for risk factors. However, when the presence of IgA antibody and/or immune complexes was used for comparison, a more highly significant association was found that was to an extent independent of other cardiac risk factors (smoking, hypertension, cholesterol).
The Finnish group's paper in this issue of the journal6 extends the association of immune complexes to 46 patients with angiographically verified chronic CAD compared with random control subjects collected in Helsinki. However, in addition to finding more frequent immune complexes with Chlamydia LPS (41% versus 15%), they also dissociated circulating immune complexes and identified C. pneumoniae protein-specific antibody. The difference between cases and controls was of greater statistical significance for those with either one or both of the immune complexes (74% versus 24%). The antibody in the "protein-specific immune complexes" was shown to be specific for C. pneumoniae both in the serological test and by immunoblot. This adds another probable marker of C. pneumoniae infection to the others previously associated with CAD.
There have now been reports from other groups supporting the association of TWAR antibody and CVD. Thom TWAR protein-specific antibody has added another dimension to these seroepidemiological studies.
Can it be concluded from these studies that there is an association between infection with Chlamydia pneumoniae, strain TWAR, and CVD? The most impressive finding is that in different laboratories using different techniques and studying patients in different stages of CVD, there was always an association of antibody (or immune complexes) specific for C. pneumoniae with disease. The association of Chlamydia with CVD does not lack biological plausibility, because each of the Chlamydia species (C. trachomatis, C. psittaci, C. pneumoniae) has been found as the cause, albeit rarely, of myocarditis, pericarditis, and endocarditis.
The possibility of C. pneumoniae infection's playing a role in the pathogenesis of atherosclerosis has received important additional support from the recent findings of A. Shor, C-C Kuo, and their colleagues. They have used morphological and molecular biological techniques to demonstrate the presence of C. pneumoniae organisms in atherosclerotic lesions of coronary arteries and aorta. One of the characteristics of the TWAR organism that differentiates it from the other Chlamydia species is a pear-shaped elementary body seen on electron microscopy. 10 Shor et all' observed structures in atheromatous lesions reminiscent of these pear-shaped elementary bodies. When sections from such lesions were examined by immunocytochemical stain with TWAR-specific monoclonal antibody, it was demonstrated that the TWAR organism was present in the atheroma. Subsequently, a total of 36 coronary arteries with atheroma were examined by both immunocytochemistry and the polymerase chain reaction for TWAR-specific DNA. The organism was demonstrated in 20 of the 36 specimens by one or both of the methods. 12 The organisms were found in atheromatous lesions from early (fatty streaks) to late (fibrocalcific) stages but not in normal vessels of the same individuals or in persons without disease. The observation has been extended to lesions in aortas and to tissue removed at coronary atherectomy collected in Seattle.13"4 The organisms were found in both macrophages and smooth muscle cells.
C. pneumoniae was first described less than 10 years ago, and its role in acute respiratory infection is still being worked out. Data showing an association with atherosclerosis are intriguing and certainly indicate the need for vigorous investigation. However, there is as yet no basis for conclusions concerning a pathogenetic role for the organism in atherosclerosis.
